Rep. Lloyd Doggett Purchases Shares of Johnson & Johnson (NYSE:JNJ)

Key Points

• Rep. Lloyd Doggett purchased between $1,001 and $15,000 of Johnson & Johnson shares on September 8, alongside purchases of Home Depot, PPG Industries, IBM and Procter & Gamble.
• Johnson & Johnson recently beat quarterly earnings and revenue estimates, with EPS of $2.90 and revenue of $25.31 billion. The company pays a quarterly dividend of $1.34, equivalent to a 2.1% annualized yield.
• Analysts maintain a consensus “Moderate Buy” rating with an average price target of $276.22, citing momentum in Innovative Medicine and J&J’s defensive dividend profile. However, the company faces MedTech pressure and a potential 2027 patent cliff that could expose roughly $4 billion in revenue.

Representative Lloyd Doggett (Democratic-Texas) recently bought shares of Johnson & Johnson NYSE: JNJ. In a filing disclosed on October 5th, the Representative disclosed that they had bought between $1,001 and $15,000 in Johnson & Johnson stock on September 8th.

Representative Lloyd Doggett also recently made the following trade(s):

• Purchased $1,001 - $15,000 in shares of Home Depot NYSE: HD on 9/17/2026.
• Purchased $1,001 - $15,000 in shares of PPG Industries NYSE: PPG on 9/11/2026.
• Purchased $1,001 - $15,000 in shares of International Business Machines NYSE: IBM on 9/10/2026.
• Purchased $1,001 - $15,000 in shares of Procter & Gamble NYSE: PG on 8/17/2026.

Johnson & Johnson Stock Performance

NYSE:JNJ opened at $254.85 on Wednesday. Johnson & Johnson has a 52 week low of $182.94 and a 52 week high of $281.07. The company has a fifty day simple moving average of $265.86 and a two-hundred day simple moving average of $248.63. The company has a quick ratio of 0.81, a current ratio of 1.09 and a debt-to-equity ratio of 0.44. The company has a market cap of $614.17 billion, a price-to-earnings ratio of 29.53, a price-to-earnings-growth ratio of 2.48 and a beta of 0.21.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its earnings results on Wednesday, July 15th. The company reported $2.90 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.84 by $0.06. Johnson & Johnson had a return on equity of 32.42% and a net margin of 21.48%.The firm had revenue of $25.31 billion during the quarter, compared to analyst estimates of $25.06 billion. During the same period last year, the business posted $2.77 earnings per share. Johnson & Johnson's revenue was up 6.6% compared to the same quarter last year. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. As a group, equities analysts anticipate that Johnson & Johnson will post 11.54 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 8th. Shareholders of record on Tuesday, August 25th were paid a $1.34 dividend. The ex-dividend date was Tuesday, August 25th. This represents a $5.36 annualized dividend and a dividend yield of 2.1%. Johnson & Johnson's payout ratio is 62.11%.

Insider Buying and Selling at Johnson & Johnson

In related news, EVP Jennifer Taubert sold 15,000 shares of the stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $263.36, for a total value of $3,950,400.00. Following the transaction, the executive vice president directly owned 194,451 shares in the company, valued at $51,210,615.36. This represents a 7.16% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Vanessa Broadhurst sold 23,054 shares of the firm's stock in a transaction that occurred on Monday, July 20th. The shares were sold at an average price of $251.27, for a total transaction of $5,792,778.58. Following the completion of the transaction, the executive vice president directly owned 23,003 shares in the company, valued at approximately $5,779,963.81. The trade was a 50.06% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders sold 87,569 shares of company stock valued at $23,064,544. 0.16% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of JNJ. Silver Coast Investments LLC boosted its holdings in Johnson & Johnson by 3.8% in the second quarter. Silver Coast Investments LLC now owns 1,066 shares of the company's stock valued at $271,000 after acquiring an additional 39 shares during the last quarter. Townsend Asset Management Corp NC ADV lifted its position in Johnson & Johnson by 0.6% during the 2nd quarter. Townsend Asset Management Corp NC ADV now owns 6,418 shares of the company's stock valued at $1,630,000 after purchasing an additional 39 shares during the period. Triumph Capital Management lifted its position in Johnson & Johnson by 1.6% during the 2nd quarter. Triumph Capital Management now owns 2,531 shares of the company's stock valued at $643,000 after purchasing an additional 39 shares during the period. Denali Advisors LLC boosted its stake in shares of Johnson & Johnson by 1.2% in the 2nd quarter. Denali Advisors LLC now owns 3,305 shares of the company's stock valued at $839,000 after purchasing an additional 40 shares during the last quarter. Finally, Beaird Harris Wealth Management LLC grew its position in shares of Johnson & Johnson by 1.8% during the 4th quarter. Beaird Harris Wealth Management LLC now owns 2,422 shares of the company's stock worth $501,000 after buying an additional 42 shares during the period. Institutional investors and hedge funds own 69.55% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the company. Johnson Rice reiterated a "buy" rating on shares of Johnson & Johnson in a research note on Monday, August 3rd. Royal Bank Of Canada upped their target price on shares of Johnson & Johnson from $287.00 to $290.00 and gave the stock an "outperform" rating in a research note on Tuesday. Scotiabank reaffirmed an "outperform" rating and issued a $305.00 target price on shares of Johnson & Johnson in a report on Thursday, July 16th. Argus set a $300.00 price target on shares of Johnson & Johnson in a report on Wednesday, July 29th. Finally, Stifel Nicolaus set a $260.00 price objective on shares of Johnson & Johnson in a research report on Wednesday, July 15th. One analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $276.22.

Key Headlines Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Innovative Medicines is offsetting MedTech pressure. RBC Capital Markets said accelerating momentum in J&J’s Innovative Medicines business is helping counter persistent headwinds in MedTech. New drug launches and portfolio diversification remain key reasons analysts see support for the shares. Johnson & Johnson's Innovative Medicines Momentum Offsets MedTech Headwinds
• Positive Sentiment: Defensive dividend characteristics are attracting investors. Analysts continue to highlight J&J’s diversified healthcare portfolio, recurring demand and dividend reliability as advantages during an economic downturn. Those qualities may support the stock’s valuation and limit downside volatility. Looking for a Dividend Stock That Can Weather a Downturn?
• Positive Sentiment: MedTech could improve later in the year. While Abiomed and broader competitive pressures weighed on the segment, Vision, Orthopedics and Surgery may produce a stronger second half and help restore growth. Can J&J's MedTech Business Rebound in Q3 After Q2 Slowdown?
• Neutral Sentiment: Investors are focused on the October 13 earnings report. Recent commentary questions whether J&J has the setup for another earnings beat, making upcoming results and management’s guidance important near-term catalysts. The company previously exceeded EPS and revenue expectations and forecast fiscal 2026 EPS of $11.60–$11.75.
• Negative Sentiment: The 2027 patent cliff remains the main overhang. Articles warn that roughly $4 billion of revenue may be exposed when key patents expire in 2027. Investors are therefore evaluating whether J&J’s drug pipeline and replacement launches can offset the loss, rather than focusing only on the next quarter’s EPS. The Next Patent Cliff Will Test a Replacement Engine
• Neutral Sentiment: Management is emphasizing artificial intelligence. CEO Joaquin Duato described AI as a force multiplier that J&J needs to embrace, but the interview offered limited near-term financial detail. Johnson & Johnson CEO Says AI Has to Be Embraced

About Representative Doggett

Lloyd Doggett (Democratic Party) is a member of the U.S. House, representing Texas' 37th Congressional District. He assumed office on January 3, 2023. His current term ends on January 3, 2027. Doggett (Democratic Party) is running for re-election to the U.S. House to represent Texas' 37th Congressional District. He declared candidacy for the 2026 election. Lloyd Doggett was born in Austin, Texas. Doggett graduated from Austin High School in 1964. He earned a B.A. from the University of Texas at Austin in 1967 and a J.D. from the University of Texas in 1970. Doggett's career experience includes working as an adjunct professor with the University of Texas School of Law. In the 116th Congress, Doggett served on the House Ways & Means Committee, and he co-founded the House Prescription Drug Taskforce.

Johnson & Johnson Company Profile

Johnson & Johnson NYSE: JNJ is a global healthcare company that develops, manufactures and markets products through two primary business segments: Innovative Medicine and MedTech. Its operations serve patients, healthcare professionals and consumers in markets around the world.

The Innovative Medicine segment focuses on prescription medicines in areas including immunology, oncology, neuroscience, cardiovascular and metabolic disease, infectious diseases, and pulmonary hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.